NCT05010005View on ClinicalTrials.gov

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
T-cell LymphomasNK-Cell LymphomasT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocyte Leukemia
Interventions
DRUG

Ruxolitinib

Ruxolitinib 20mg BID

DRUG

Duvelisib

Duvelisib 25mg, 50mg, or 75mg BID

Trial Locations (9)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

33125

ACTIVE_NOT_RECRUITING

University of Miami (Data Collection Only), Miami

02115

RECRUITING

Dana Farber Cancer Institute, Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER